A Phase 2, Open-label, Multi-institutional Study to Evaluate the Efficacy of Induction Therapy With MK-3475 and ASG-22CE Followed by Radiation Therapy With MK-3475 in Patients With MIBC Who Are Unfit for or Refuse Radical Cystectomy
Latest Information Update: 01 Sep 2025
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms PEVRAD
Most Recent Events
- 25 Oct 2023 Status changed from not yet recruiting to recruiting.
- 02 Jun 2023 New trial record